Search for "polycycles" in Full Text gives 18 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2024, 20, 1839–1879, doi:10.3762/bjoc.20.162
Graphical Abstract
Scheme 1: Mechanism of the GBB reaction.
Scheme 2: Comparison of the performance of Sc(OTf)3 with some RE(OTf)3 in a model GBB reaction. Conditions: a...
Scheme 3: Comparison of the performance of various Brønsted acid catalysts in the synthesis of GBB adduct 6. ...
Scheme 4: Synthesis of Brønsted acidic ionic liquid catalyst 7. Conditions: a) neat, 60 °C, 24 h; b) TfOH, DC...
Scheme 5: Aryliodonium derivatives as organic catalysts in the GBB reaction. In the box the proposed binding ...
Scheme 6: DNA-encoded GBB reaction in micelles made of amphiphilic polymer 13. Conditions: a) 13 (50 equiv), ...
Scheme 7: GBB reaction catalyzed by cyclodextrin derivative 14. Conditions: a) 14 (1 mol %), water, 100 °C, 4...
Scheme 8: Proposed mode of activation of CALB. a) activation of the substrates; b) activation of the imine; c...
Scheme 9: One-pot GBB reaction–Suzuki coupling with a bifunctional hybrid biocatalyst. Conditions: a) Pd(0)-C...
Scheme 10: GBB reaction employing 5-HMF (23) as carbonyl component. Conditions: a) TFA (20 mol %), EtOH, 60 °C...
Scheme 11: GBB reaction with β-C-glucopyranosyl aldehyde 26. Conditions: a) InCl3 (20 mol %), MeOH, 70 °C, 2–3...
Scheme 12: GBB reaction with diacetylated 5-formyldeoxyuridine 29, followed by deacetylation of GBB adduct 30....
Scheme 13: GBB reaction with glycal aldehydes 32. Conditions: a) HFIP, 25 °C, 2–4 h.
Scheme 14: Vilsmeier–Haack formylation of 6-β-acetoxyvouacapane (34) and subsequent GBB reaction. Conditions: ...
Scheme 15: GBB reaction of 4-formlyl-PCP 37. Conditions: a) HOAc or HClO4, MeOH/DCM (2:3), rt, 3 d.
Scheme 16: GBB reaction with HexT-aldehyde 39. Conditions: a) 39 (20 nmol) and amidine (20 μmol), MeOH, rt, 6 ...
Scheme 17: GBB reaction of 2,4-diaminopirimidine 41. Conditions: a) Sc(OTf)3 (20 mol %), MeCN, 120 °C (MW), 1 ...
Scheme 18: Synthesis of N-edited guanine derivatives from 3,6-diamine-1,2,4-triazin-5-one 44. Conditions: a) S...
Scheme 19: Synthesis of 2-aminoimidazoles 49 by a Mannich-3CR followed by a one-pot intramolecular oxidative a...
Scheme 20: On DNA Suzuki–Miyaura reaction followed by GBB reaction. Conditions: a) CsOH, sSPhos-Pd-G2; b) AcOH...
Scheme 21: One-pot cascade synthesis of 5-iminoimidazoles. Conditions: a) Na2SO4, DMF, 220 °C (MW).
Scheme 22: GBB reaction of 5-amino-1H-imidazole-4-carbonile 57. Conditions: a) HClO4 (5 mol %), MeOH, rt, 24 h....
Scheme 23: One-pot cascade synthesis of indole-imidazo[1,2,a]pyridine hybrids. In blue the structural motif in...
Scheme 24: One-pot cascade synthesis of fused polycyclic indoles 67 or 69 from indole-3-carbaldehyde. Conditio...
Scheme 25: One-pot cascade synthesis of linked- and bridged polycyclic indoles from indole-2-carbaldehyde (70)...
Scheme 26: One-pot cascade synthesis of pentacyclic dihydroisoquinolines (X = N or CH). In blue the structural...
Scheme 27: One-pot stepwise synthesis of imidazopyridine-fused benzodiazepines 85. Conditions: a) p-TsOH (20 m...
Scheme 28: One-pot stepwise synthesis of benzoxazepinium-fused imidazothiazoles 89. Conditions: a) Yb(OTf)3 (2...
Scheme 29: One-pot stepwise synthesis of fused imidazo[4,5,b]pyridines 95. Conditions: a) HClO4, MeOH, rt, ove...
Scheme 30: Synthesis of heterocyclic polymers via the GBB reaction. Conditions: a) p-TsOH, EtOH, 70 °C, 24 h.
Scheme 31: One-pot multicomponent reaction towards the synthesis of covalent organic frameworks via the GBB re...
Scheme 32: One-pot multicomponent reaction towards the synthesis of covalent organic frameworks via the GBB re...
Scheme 33: GBB-like multicomponent reaction towards the synthesis of benzothiazolpyrroles (X = S) and benzoxaz...
Scheme 34: GBB-like multicomponent reaction towards the formation of imidazo[1,2,a]pyridines. Conditions: a) I2...
Scheme 35: Post-functionalization of GBB products via Ugi reaction. Conditions a) HClO4, DMF, rt, 24 h; b) MeO...
Scheme 36: Post-functionalization of GBB products via Click reaction. Conditions: a) solvent-free, 150 °C, 24 ...
Scheme 37: Post-functionalization of GBB products via cascade alkyne–allene isomerization–intramolecular nucle...
Scheme 38: Post-functionalization of GBB products via metal-catalyzed intramolecular N-arylation. In red and b...
Scheme 39: Post-functionalization of GBB products via isocyanide insertion (X = N or CH). Conditions: a) HClO4...
Scheme 40: Post-functionalization of GBB products via intramolecular nucleophilic addition to nitriles. Condit...
Scheme 41: Post-functionalization of GBB products via Pictet–Spengler cyclization. Conditions: a) 4 N HCl/diox...
Scheme 42: Post-functionalization of GBB products via O-alkylation. Conditions: a) TFA (20 mol %), EtOH, 120 °...
Scheme 43: Post-functionalization of GBB products via macrocyclization (X = -CH2CH2O-, -CH2-, -(CH2)4-). Condi...
Figure 1: Antibacterial activity of GBB-Ugi adducts 113 on both Gram-negative and Gram-positive strains.
Scheme 44: GBB multicomponent reaction using trimethoprim as the precursor. Conditions: a) Yb(OTf)3 or Y(OTf)3...
Figure 2: Antibacterial activity of GBB adducts 152 against MRSA and VRE; NA = not available.
Figure 3: Antibacterial activity of GBB adduct 153 against Leishmania amazonensis promastigotes and amastigot...
Figure 4: Antiviral and anticancer evaluation of the GBB adducts 154a and 154b. In vitro antiproliferative ac...
Figure 5: Anticancer activity of the GBB-furoxan hybrids 145b, 145c and 145d determined through antiprolifera...
Scheme 45: Synthesis and anticancer activity of the GBB-gossypol conjugates. Conditions: a) Sc(OTf)3 (10 mol %...
Figure 6: Anticancer activity of polyheterocycles 133a and 136a against human neuroblastoma. Clonogenic assay...
Figure 7: Development of GBB-adducts 158a and 158b as PD-L1 antagonists. HTRF assays were carried out against...
Figure 8: Development of imidazo[1,2-a]pyridines and imidazo[1,2-a]pyrazines as TDP1 inhibitors. The SMM meth...
Figure 9: GBB adducts 164a–c as anticancer through in vitro HDACs inhibition assays. Additional cytotoxic ass...
Figure 10: GBB adducts 165, 166a and 166b as anti-inflammatory agents through HDAC6 inhibition; NA = not avail...
Scheme 46: GBB reaction of triphenylamine 167. Conditions: a) NH4Cl (10 mol %), MeOH, 80 °C (MW), 1 h.
Scheme 47: 1) Modified GBB-3CR. Conditions: a) TMSCN (1.0 equiv), Sc(OTf)3 (0.2 equiv), MeOH, 140 °C (MW), 20 ...
Scheme 48: GBB reaction to assemble imidazo-fused heterocycle dimers 172. Conditions: a) Sc(OTf)3 (20 mol %), ...
Figure 11: Model compounds 173 and 174, used to study the acid/base-triggered reversible fluorescence response...
Beilstein J. Org. Chem. 2023, 19, 778–788, doi:10.3762/bjoc.19.58
Graphical Abstract
Scheme 1: Photochemical behavior of terarylenes containing an allomaltol fragment.
Scheme 2: Synthesis of starting compounds 9. Reaction conditions: 13 (1 mmol), NH2CN (14, 3 mmol, 0.13 g), Et...
Scheme 3: Proposed mechanism for the formation of compounds 9.
Scheme 4: Synthesis of methylated derivatives 10. Reaction conditions: 9 (1 mmol), MeI (3 mmol, 0.43 g), K2CO3...
Figure 1: 1H NMR monitoring of the photoreaction of compound 10a under UV irradiation (365 nm) in DMSO-d6 sol...
Figure 2: The crystal structure of compound 11a (one of two polymorph modifications; p = 50%), CCDC 2248033.
Scheme 5: Photochemical synthesis of compounds 11 and 12.
Scheme 6: Proposed mechanism for the studied photoreaction.
Scheme 7: Synthesis of compounds 11g–j starting from pyrimidines 9. Reaction conditions: 9 (0.5 mmol), DMF (1...
Figure 3: One of crystallographically unique molecules of 11g (p = 50%), CCDC 2248035.
Scheme 8: Synthesis of photoproducts 12. Reaction conditions: method A) 10 (0.5 mmol), DMF (15 mL) irradiatio...
Beilstein J. Org. Chem. 2021, 17, 819–865, doi:10.3762/bjoc.17.71
Graphical Abstract
Figure 1: Marketed drugs with acridine moiety.
Scheme 1: Synthesis of 4-arylacridinediones.
Scheme 2: Proposed mechanism for acridinedione synthesis.
Scheme 3: Synthesis of tetrahydrodibenzoacridinones.
Scheme 4: Synthesis of naphthoacridines.
Scheme 5: Plausible mechanism for naphthoacridines.
Figure 2: Benzoazepines based potent molecules.
Scheme 6: Synthesis of azepinone.
Scheme 7: Proposed mechanism for azepinone formation.
Scheme 8: Synthesis of benzoazulenen-1-one derivatives.
Scheme 9: Proposed mechanism for benzoazulene-1-one synthesis.
Figure 3: Indole-containing pharmacologically active molecules.
Scheme 10: Synthesis of functionalized indoles.
Scheme 11: Plausible mechanism for the synthesis of functionalized indoles.
Scheme 12: Synthesis of spirooxindoles.
Scheme 13: Synthesis of substituted spirooxindoles.
Scheme 14: Plausible mechanism for the synthesis of substituted spirooxindoles.
Scheme 15: Synthesis of pyrrolidinyl spirooxindoles.
Scheme 16: Proposed mechanism for pyrrolidinyl spirooxindoles.
Figure 4: Pyran-containing biologically active molecules.
Scheme 17: Synthesis of functionalized benzopyrans.
Scheme 18: Plausible mechanism for synthesis of benzopyran.
Scheme 19: Synthesis of indoline-spiro-fused pyran derivatives.
Scheme 20: Proposed mechanism for indoline-spiro-fused pyran.
Scheme 21: Synthesis of substituted naphthopyrans.
Figure 5: Marketed drugs with pyrrole ring.
Scheme 22: Synthesis of tetra-substituted pyrroles.
Scheme 23: Mechanism for silica-supported PPA-SiO2-catalyzed pyrrole synthesis.
Scheme 24: Synthesis of pyrrolo[1,10]-phenanthrolines.
Scheme 25: Proposed mechanism for pyrrolo[1,10]-phenanthrolines.
Figure 6: Marketed drugs and molecules containing pyrimidine and pyrimidinones skeletons.
Scheme 26: MWA-MCR pyrimidinone synthesis.
Scheme 27: Two proposed mechanisms for pyrimidinone synthesis.
Scheme 28: MWA multicomponent synthesis of dihydropyrimidinones.
Scheme 29: Proposed mechanism for dihydropyrimidinones.
Figure 7: Biologically active fused pyrimidines.
Scheme 30: MWA- MCR for the synthesis of pyrrolo[2,3-d]pyrimidines.
Scheme 31: Proposed mechanism for pyrrolo[2,3-d]pyrimidines.
Scheme 32: Synthesis of substituted pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 33: Probable pathway for pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 34: Synthesis of pyridopyrimidines.
Scheme 35: Plausible mechanism for the synthesis of pyridopyrimidines.
Scheme 36: Synthesis of dihydropyridopyrimidine and dihydropyrazolopyridine.
Scheme 37: Proposed mechanism for the formation of dihydropyridopyrimidine.
Scheme 38: Synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 39: Plausible mechanism for the synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 40: Synthesis of decorated imidazopyrimidines.
Scheme 41: Proposed mechanism for imidazopyrimidine synthesis.
Figure 8: Pharmacologically active molecules containing purine bases.
Scheme 42: Synthesis of aza-adenines.
Scheme 43: Synthesis of 5-aza-7-deazapurines.
Scheme 44: Proposed mechanism for deazapurines synthesis.
Figure 9: Biologically active molecules containing pyridine moiety.
Scheme 45: Synthesis of steroidal pyridines.
Scheme 46: Proposed mechanism for steroidal pyridine.
Scheme 47: Synthesis of N-alkylated 2-pyridones.
Scheme 48: Two possible mechanisms for pyridone synthesis.
Scheme 49: Synthesis of pyridone derivatives.
Scheme 50: Postulated mechanism for synthesis of pyridone.
Figure 10: Biologically active fused pyridines.
Scheme 51: Benzimidazole-imidazo[1,2-a]pyridines synthesis.
Scheme 52: Mechanism for the synthesis of benzimidazole-imidazo[1,2-a]pyridines.
Scheme 53: Synthesis of pyrazolo[3,4-b]pyridine-5-spirocycloalkanedione derivatives.
Scheme 54: Proposed mechanism for spiro-pyridines.
Scheme 55: Functionalized macrocyclane-fused pyrazolo[3,4-b]pyridine derivatives.
Scheme 56: Mechanism postulated for macrocyclane-fused pyrazolo[3,4-b]pyridine.
Scheme 57: Generation of pyrazolo[3,4-b]pyridines.
Scheme 58: Proposed mechanism for the synthesis of pyrazolo[3,4-b]pyridines.
Scheme 59: Proposed mechanism for the synthesis of azepinoindole.
Figure 11: Pharmaceutically important molecules with quinoline moiety.
Scheme 60: Povarov-mediated quinoline synthesis.
Scheme 61: Proposed mechanism for Povarov reaction.
Scheme 62: Synthesis of pyrazoloquinoline.
Scheme 63: Plausible mechanism for pyrazoloquinoline synthesis.
Figure 12: Quinazolinones as pharmacologically significant scaffolds.
Scheme 64: Four-component reaction for dihydroquinazolinone.
Scheme 65: Proposed mechanism for dihydroquinazolinones.
Scheme 66: Synthesis purine quinazolinone and PI3K-δ inhibitor.
Scheme 67: Synthesis of fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 68: Proposed mechanism for fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 69: On-water reaction for synthesis of thiazoloquinazolinone.
Scheme 70: Proposed mechanism for the thiazoloquinazolinone synthesis.
Scheme 71: β-Cyclodextrin-mediated synthesis of indoloquinazolinediones.
Scheme 72: Proposed mechanism for synthesis of indoloquinazolinediones.
Figure 13: Triazoles-containing marketted drugs and pharmacologically active molecules.
Scheme 73: Cu(I) DAPTA-catalyzed 1,2,3-triazole formation.
Scheme 74: Mechanism for Cu(I) DAPTA-catalyzed triazole formation.
Scheme 75: Synthesis of β-hydroxy-1,2,3-triazole.
Scheme 76: Proposed mechanism for synthesis of β-hydroxy-1,2,3-triazoles.
Scheme 77: Synthesis of bis-1,2,4-triazoles.
Scheme 78: Proposed mechanism for bis-1,2,4-triazoles synthesis.
Figure 14: Thiazole containing drugs.
Scheme 79: Synthesis of a substituted thiazole ring.
Scheme 80: Synthesis of pyrazolothiazoles.
Figure 15: Chromene containing drugs.
Scheme 81: Magnetic nanocatalyst-mediated aminochromene synthesis.
Scheme 82: Proposed mechanism for the synthesis of chromenes.
Beilstein J. Org. Chem. 2020, 16, 2212–2259, doi:10.3762/bjoc.16.186
Graphical Abstract
Figure 1: Representation of corannulene (1) and sumanene (2), the subunits of fullerene (C60).
Scheme 1: Mehta’s unsuccessful effort for the synthesis of sumanene scaffold 2.
Scheme 2: First synthesis of sumanene 2 by Sakurai et al. from norbornadiene 10.
Scheme 3: Synthesis of trimethylsumanene 28 from easily accessible norbornadiene (10).
Scheme 4: Generation of anions 29–31 and the preparation of tris(trimethylsilyl)sumanene 32.
Scheme 5: Synthesis of tri- and hexa-substituted sumanene derivatives.
Scheme 6: Synthesis of bowl-shaped π-extended sumanene derivatives 37a–f.
Scheme 7: Synthesis of monooxasumanene 38, trioxosumanene 40 along with imination of them.
Scheme 8: Synthesis of trimethylsumanenetrione 46 and exo-functionalized products 45a,b.
Scheme 9: Synthesis of bisumanenylidene 47 and sumanene dimer 48 from 2.
Scheme 10: The mono-substitution of 2 to generate diverse mono-sumanene derivatives 49a–d.
Scheme 11: Synthesis of sumanene building block 53 useful for further extension.
Scheme 12: Synthesis of hexafluorosumanene derivative 55 by Sakurai and co-workers.
Scheme 13: Preparation of sumanene-based carbene 60 and its reaction with cyclohexane.
Scheme 14: Barton–Kellogg reaction for the synthesis of sterically hindered alkenes.
Scheme 15: Synthesis of hydroxysumanene 68 by employing Baeyer–Villiger oxidation.
Scheme 16: Synthesis of sumanene derivatives having functionality at an internal carbon.
Scheme 17: Mechanism for nucleophilic substitution reaction at the internal carbon.
Scheme 18: Synthesis of diverse monosubstituted sumanene derivatives.
Scheme 19: Synthesis of di- and trisubstituted sumanene derivatives from sumanene (2).
Scheme 20: Preparation of monochlorosumanene 88 and hydrogenation of sumanene (2).
Scheme 21: The dimer 90 and bissumanenyl 92 achieved from halosumannes.
Scheme 22: Pyrenylsumanene 93 involving the Suzuki-coupling as a key transformation.
Scheme 23: Synthesis of various hexaarylsumanene derivatives using the Suzuki-coupling reaction.
Scheme 24: Synthesis of hexasubstituted sumanene derivatives 96 and 97.
Scheme 25: Synthesis of thioalkylsumanenes via an aromatic nucleophilic substitution reaction.
Scheme 26: Synthesis of tris(ethoxycarbonylethenyl)sumanene derivative 108.
Scheme 27: Synthesis of ferrocenyl-based sumanene derivatives.
Scheme 28: Synthesis of sumanenylferrocene architectures 118 and 119 via Negishi coupling.
Scheme 29: Diosmylation and the synthesis of phenylboronate ester 121 of sumanene.
Scheme 30: Synthesis of the iron-complex of sumanene.
Scheme 31: Synthesis of tri- and mononuclear sumanenyl zirconocene complexes.
Scheme 32: Synthesis of [CpRu(η6-sumanene)]PF6.
Scheme 33: Preparation of sumanene-based porous coordination networks 127 (spherical tetramer units) and 128 (...
Scheme 34: Synthesis of sumanenylhafnocene complexes 129 and 130.
Scheme 35: Synthesis of 134 and 135 along with PdII coordination complex 136.
Scheme 36: Synthesis of alkali metals sumanene complex K7(C21H102−)2(C21H93−)·8THF (137) containing di- and tr...
Scheme 37: The encapsulation of a Cs+ ion between two sumanenyl anions.
Scheme 38: Synthesis of monothiasumanene 140 and dithiasumanene 141 from 139.
Scheme 39: Synthesis of trithiasumanene 151 by Otsubo and his co-workers.
Scheme 40: Synthesis of trithiasumanene derivatives 155 and 156.
Scheme 41: Synthetic route towards hexathiolated trithiasumanenes 158.
Scheme 42: Synthesis of triselenasumanene 160 by Shao and teammates.
Scheme 43: Synthesis of tritellurasumanene derivatives from triphenylene skeletons.
Scheme 44: Synthesis of pyrazine-fused sumanene architectures through condensation reaction.
Scheme 45: Treatment of the trichalcogenasumanenes with diverse oxidative reagents.
Scheme 46: Ring-opening reaction with H2O2 and oxone of heterasumanenes 178 and 179.
Scheme 47: Synthesis of polycyclic compounds from sumanene derivatives.
Scheme 48: Synthesis of diimide-based heterocycles reported by Shao’s and co-workers.
Scheme 49: Synthesis of pristine trichalcogenasumanenes, 151, 205, and 206.
Scheme 50: Synthesis of trichalcogenasumanenes via hexaiodotriphenylene precursor 208.
Scheme 51: Synthesis of trisilasumanenes 214 and 215.
Scheme 52: Synthesis of trisilasumanene derivatives 218 and 219.
Scheme 53: Synthesis of novel trigermasumanene derivative 223.
Scheme 54: An attempt towards the synthesis of tristannasumanene derivative 228.
Scheme 55: Synthesis of triphosphasumanene trisulfide 232 from commercially available 229.
Scheme 56: The doping of sumanene derivatives with chalcogens (S, Se, Te) and phosphorus.
Scheme 57: Synthesis of heterasumanene containing three different heteroatoms.
Scheme 58: Synthesis of trichalcogenasumanene derivatives 240 and 179.
Scheme 59: Preparation of trichalcogenasumanenes 245 and 248.
Scheme 60: Design and synthesis of trichalcogenasumanene derivatives 252 and 178.
Scheme 61: Synthesis of spirosumanenes 264–269 and non-spiroheterasumanenes 258–263.
Scheme 62: Synthesis of sumanene-type hetero polycyclic compounds.
Scheme 63: Synthesis of triazasumanenes 288 and its sulfone congener 287.
Scheme 64: Synthesis of C3-symmetric chiral triaryltriazasumanenes via cross-coupling reaction.
Scheme 65: Synthesis of mononaphthosumanene 293 using Suzuki coupling as a key step.
Scheme 66: Synthesis of di- and trinaphthosumanene derivatives 302–304.
Scheme 67: Synthesis of hemifullerene skeletons by Hirao’s group.
Scheme 68: Design and construction of C70 fragment from a C60 sumanene fragment.
Beilstein J. Org. Chem. 2020, 16, 1320–1334, doi:10.3762/bjoc.16.113
Graphical Abstract
Figure 1: Fused aza-hetero polycyclic frames and natural pyrrolizine- and isoindole-containing alkaloids.
Scheme 1: Synthetic approaches for the preparation of pyrrolo-fused aza-hetero polycyclic frames.
Scheme 2: Preparation of 1,2-substituted pyrroles 8a–f and 8i,j.
Scheme 3: Diels–Alder cycloadditions of pyrroles 8a–j and 16a–b with maleimides 7b–c.
Figure 2: Structures of 9m (a) and 10m (b) as determined by single-crystal X-ray diffraction crystallography ...
Scheme 4: Pd(0)-catalyzed intramolecular Heck cross-coupling reaction of 2-vinylpyrroles 8c,d and 8g.
Scheme 5: Synthesis of 2-vinylpyrroles 8k,l and their Pd(0)-catalyzed intramolecular Heck cross-coupling to p...
Scheme 6: Diastereoselective Diels–Alder reaction of pyrrolo[2,1-a]isoindole 18a with 7c.
Scheme 7: Synthetic approach to the fused aza-heterocyclic pentacycle 12.
Figure 3: M06-2X/6-31+G(d,p) Optimized geometry for each of the SCs (a and d), TSs (b and e) and ADs (c and f...
Figure 4: M06-2X/6-31+G(d,p) Optimized geometry for each of the TSs of the Diels–Alder reactions of dienes 8b...
Figure 5: M06-2X/6-31+G(d,p) Optimized geometry of the endo SCs (a) and TSs (b) for the Diels–Alder reaction ...
Beilstein J. Org. Chem. 2019, 15, 2623–2630, doi:10.3762/bjoc.15.255
Graphical Abstract
Scheme 1: Two modes of reactions of alkynes by silver catalysis.
Scheme 2: Reactions of ynamides or ynol ethers with isoxazoles by transition metal catalysis.
Figure 1: Selected bioactive molecules containing the 5-amino-1H-pyrrole-3-carboxamide motif.
Scheme 3: Reactions of ynamide 4a with different isoxazoles 5, 7 and 8a.
Figure 2: Scope with regard to ynamide 4. All reactions were carried out with ynamide 4 (0.2 mmol), isoxazole ...
Figure 3: Scope with regard to the 5-aminoisoxazole 8 (see Figure 2). aReaction conditions: 2.0 equiv of 8e, 100 °C.
Figure 4: Molecular structure in the solid state of compound 10ad.
Scheme 4: A gram-scale experiment.
Scheme 5: Mechanistic hypotheses for Ag-catalyzed reaction of ynamide 4a with aminoisoxazole 8a.
Scheme 6: Possible reaction routes of intermediate C.
Beilstein J. Org. Chem. 2018, 14, 2708–2714, doi:10.3762/bjoc.14.248
Graphical Abstract
Scheme 1: Metathesis of norbornene derivatives.
Figure 1: Structures of retigeranic acids A (1a) and B (1b).
Scheme 2: Synthesis plan.
Scheme 3: Metathesis of norbornene derivatives 7a and 7b.
Figure 2: ORTEP of compound 13 (ellipsoids at 30% probability).
Scheme 4: Metathesis of the norbornene derivative 17.
Figure 3: Probable metathesis intermediates.
Beilstein J. Org. Chem. 2018, 14, 2468–2481, doi:10.3762/bjoc.14.223
Graphical Abstract
Figure 1: Various catalysts used for metathesis reactions.
Scheme 1: SM coupling and RCM protocol to substituted indene derivative 10.
Scheme 2: Synthesis of polycycles via SM and RCM approach.
Figure 2: Various angucyclines.
Scheme 3: SM coupling and RCM protocol to the benz[a]anthracene skeleton 26.
Scheme 4: Synthesis of substituted spirocycles via RCM and SM sequence.
Scheme 5: Synthesis of highly functionalized bis-spirocyclic derivative 37.
Scheme 6: Synthesis of spirofluorene derivatives via RCM and SM coupling sequence.
Scheme 7: Synthesis of truxene derivatives via RCM and SM coupling.
Scheme 8: Synthesis of substituted isoquinoline derivative via SM and RCM protocol.
Scheme 9: Synthesis to 8-aryl substituted coumarin 64 via RCM and SM sequence.
Scheme 10: Synthesis of cyclic sulfoximine 70 via SM and RCM as key steps.
Scheme 11: Synthesis of 1-benzazepine derivative 75 via SM and RCM as key steps.
Scheme 12: Synthesis of naphthoxepine derivative 79 via RCM followed by SM coupling.
Scheme 13: Sequential CM and SM coupling approach to Z-stilbene derivative 85.
Scheme 14: Synthesis of substituted trans-stilbene derivatives via SM coupling and RCM.
Scheme 15: Synthesis of biaryl derivatives via sequential EM, DA followed by SM coupling.
Scheme 16: Synthesis of the dibenzocyclooctadiene core of schisandrene.
Scheme 17: Synthesis of cyclophane 115 via SM coupling and RCM as key steps.
Scheme 18: Synthesis of cyclophane 120 and 122 via SM coupling and RCM as key steps.
Scheme 19: Synthesis of cyclophanes via SM and RCM.
Scheme 20: Synthesis of MK-6325 (141) via RCM and SM coupling.
Beilstein J. Org. Chem. 2017, 13, 639–643, doi:10.3762/bjoc.13.62
Graphical Abstract
Scheme 1: Examples of metal-catalyzed transformations of 1,11-dien-6-ynes.
Scheme 2: Cobalt-catalyzed cycloisomerizations of 1,11-dien-6-ynes.
Scheme 3: Possible mechanism for formation of the compounds 2–5.
Scheme 4: Cycloisomerization of the substituted dienyne 1c.
Figure 1: The substituted 1,11-dien-6-ynes that did not undergo cycloisomerization in the presence of the cob...
Beilstein J. Org. Chem. 2016, 12, 985–999, doi:10.3762/bjoc.12.97
Graphical Abstract
Figure 1: Bridged polycyclic natural products.
Figure 2: Strategic limitations.
Scheme 1: Bridged rings from N–H bond insertions.
Scheme 2: The synthesis of deoxystemodin.
Scheme 3: A model system for ingenol.
Scheme 4: Formal synthesis of platensimycin.
Scheme 5: The formal synthesis of gerryine.
Scheme 6: Copper-catalyzed bridged-ring synthesis.
Scheme 7: Factors influencing insertion selectivity.
Scheme 8: Bridged-lactam formation.
Scheme 9: The total synthesis of (+)-codeine.
Scheme 10: A model system for irroratin.
Scheme 11: The utility of 1,6-insertion.
Scheme 12: Piperidine functionalization.
Scheme 13: Wilkinson’s catalyst for C–H bond insertion.
Scheme 14: Bridgehead insertion and the total synthesis of albene and santalene.
Scheme 15: The total synthesis of neopupukean-10-one.
Scheme 16: An approach to phomoidride B.
Scheme 17: Carbene cascade for fused bicycles.
Scheme 18: Cascade formation of bridged rings.
Scheme 19: Conformational effects.
Scheme 20: Hydrazone cascade reaction.
Scheme 21: Mechanistic studies.
Scheme 22: Gold carbene formation from alkynes.
Scheme 23: Au-catalyzed bridged-bicycle formation.
Scheme 24: Gold carbene/alkyne cascade.
Scheme 25: Gold carbene/alkyne cascade with C–H bond insertion.
Scheme 26: Platinum cascades.
Scheme 27: Tungsten cascade.
Beilstein J. Org. Chem. 2015, 11, 1833–1864, doi:10.3762/bjoc.11.199
Graphical Abstract
Figure 1: Ruthenium alkylidene catalysts used in RRM processes.
Figure 2: General representation of various RRM processes.
Figure 3: A general mechanism for RRM process.
Scheme 1: RRM of cyclopropene systems.
Scheme 2: RRM of cyclopropene with catalyst 2. (i) catalyst 2 (2.5 mol %), ethylene (24, 1 atm), (ii) toluene...
Scheme 3: RRM of various cyclopropene derivatives with catalyst 2. (i) catalyst 2 (2.5 mol %), CH2Cl2 (c = 0....
Scheme 4: RRM of substituted cyclopropene system with catalyst 2.
Scheme 5: RRM of cyclobutene system with catalyst 2.
Scheme 6: RRM approach to various bicyclic compounds.
Scheme 7: RRM approach to erythrina alkaloid framework.
Scheme 8: ROM–RCM sequence to lactone derivatives.
Scheme 9: RRM protocol towards the synthesis of lactone derivative 58.
Scheme 10: RRM protocol towards the asymmetric synthesis of asteriscunolide D (61).
Scheme 11: RRM strategy towards the synthesis of various macrolide rings.
Scheme 12: RRM protocol to dipiperidine system.
Scheme 13: RRM of cyclopentene system to generate the cyclohexene systems.
Scheme 14: RRM of cyclopentene system 74.
Scheme 15: RRM approach to compound 79.
Scheme 16: RRM approach to spirocycles.
Scheme 17: RRM approach to bicyclic dihydropyrans.
Scheme 18: RCM–ROM–RCM cascade using non strained alkenyl heterocycles.
Scheme 19: First ROM–RCM–ROM–RCM cascade for the synthesis of trisaccharide 97.
Scheme 20: RRM of cyclohexene system.
Scheme 21: RRM approach to tricyclic spirosystem.
Scheme 22: RRM approach to bicyclic building block 108a.
Scheme 23: ROM–RCM protocol for the synthesis of the bicyclo[3.3.0]octene system.
Scheme 24: RRM protocol to bicyclic enone.
Scheme 25: RRM protocol toward the synthesis of the tricyclic system 118.
Scheme 26: RRM approach toward the synthesis of the tricyclic enones 122a and 122b.
Scheme 27: Synthesis of tricyclic and tetracyclic systems via RRM protocol.
Scheme 28: RRM protocol towards the synthesis of tetracyclic systems.
Scheme 29: RRM of the propargylamino[2.2.1] system.
Scheme 30: RRM of highly decorated bicyclo[2.2.1] systems.
Scheme 31: RRM protocol towards fused tricyclic compounds.
Scheme 32: RRM protocol to functionalized tricyclic systems.
Scheme 33: RRM approach to functionalized polycyclic systems.
Scheme 34: Sequential RRM approach to functionalized tricyclic ring system 166.
Scheme 35: RRM protocol to functionalized CDE tricyclic ring system of schintrilactones A and B.
Scheme 36: Sequential RRM approach to 7/5 fused bicyclic systems.
Scheme 37: Sequential ROM-RCM protocol for the synthesis of bicyclic sugar derivatives.
Scheme 38: ROM–RCM sequence of the norbornene derivatives 186 and 187.
Scheme 39: RRM approach toward highly functionalized bridge tricyclic system.
Scheme 40: RRM approach toward highly functionalized tricyclic systems.
Scheme 41: Synthesis of hexacyclic compound 203 by RRM approach.
Scheme 42: RRM approach toward C3-symmetric chiral trimethylsumanene 209.
Scheme 43: Triquinane synthesis via IMDA reaction and RRM protocol.
Scheme 44: RRM approach to polycyclic compounds.
Scheme 45: RRM strategy toward cis-fused bicyclo[3.3.0]carbocycles.
Scheme 46: RRM protocol towards the synthesis of bicyclic lactone 230.
Scheme 47: RRM approach to spiro heterocyclic compounds.
Scheme 48: RRM approach to spiro heterocyclic compounds.
Scheme 49: RRM approach to regioselective pyrrolizidine system 240.
Scheme 50: RRM approach to functionalized bicyclic derivatives.
Scheme 51: RRM approach to tricyclic derivatives 249 and 250.
Scheme 52: RRM approach to perhydroindoline derivative and spiro system.
Scheme 53: RRM approach to bicyclic pyran derivatives.
Scheme 54: RRM of various functionalized oxanorbornene systems.
Scheme 55: RRM to assemble the spiro fused-furanone core unit. (i) 129, benzene, 55 °C, 3 days; (ii) Ph3P=CH2B...
Scheme 56: RRM protocol to norbornenyl sultam systems.
Scheme 57: Ugi-RRM protocol for the synthesis of 2-aza-7-oxabicyclo system.
Scheme 58: Synthesis of spiroketal systems via RRM protocol.
Scheme 59: RRM approach to cis-fused heterotricyclic system.
Scheme 60: RRM protocol to functionalized bicyclic systems.
Scheme 61: ROM/RCM/CM cascade to generate bicyclic scaffolds.
Scheme 62: RCM of ROM/CM product.
Scheme 63: RRM protocol to bicyclic isoxazolidine ring system.
Scheme 64: RRM approach toward the total synthesis of (±)-8-epihalosaline (300).
Scheme 65: Sequential RRM approach to decalin 304 and 7/6 fused 305 systems.
Scheme 66: RRM protocol to various fused carbocyclic derivatives.
Scheme 67: RRM to cis-hydrindenol derivatives.
Scheme 68: RRM protocol towards the cis-hydrindenol derivatives.
Scheme 69: RRM approach toward the synthesis of diversed polycyclic lactams.
Scheme 70: RRM approach towards synthesis of hexacyclic compound 324.
Scheme 71: RRM protocol to generate luciduline precursor 327 with catalyst 2.
Scheme 72: RRM protocol to key building block 330.
Scheme 73: RRM approach towards the synthesis of key intermediate 335.
Scheme 74: RRM protocol to highly functionalized spiro-pyran system 339.
Scheme 75: RRM to various bicyclic polyether derivatives.
Beilstein J. Org. Chem. 2015, 11, 1373–1378, doi:10.3762/bjoc.11.148
Graphical Abstract
Figure 1: Retrosynthetic approach to polycyclic sulfones.
Scheme 1: Preparation of the sulfone 6 via oxidation.
Scheme 2: Synthesis of alkenylated sulfone derivatives.
Scheme 3: Synthesis of 10 by RRM of 2a.
Scheme 4: Synthesis of 1b using RRM.
Scheme 5: RRM of the dipentenyl sulfone 2c.
Scheme 6: RRM of the dihexenyl sulfone 2d.
Beilstein J. Org. Chem. 2015, 11, 1367–1372, doi:10.3762/bjoc.11.147
Graphical Abstract
Figure 1: Structures of diverse biologically as well as theoretically interesting molecules.
Figure 2: Retrosynthetic analysis of bis-spiro-pyrano cage compound 7.
Scheme 1: Synthesis of hexacyclic cage dione 10.
Scheme 2: Synthesis of tetrahydrofuran-based cage compounds 12 and 13.
Figure 3: (a)Optimized structure of 12, (b) optimized structure of 13.
Scheme 3: Synthesis di-allyl cage compound 11.
Scheme 4: Synthesis of spiro-pyrano cage molecules 7 and 17.
Figure 4: (a) Optimized structure of 18, (b) optimized structure of 7.
Scheme 5: Synthesis of octacyclic cage compound 18 via intramolecular DA reaction.
Scheme 6: Attempted synthesis to cage compound 20.
Beilstein J. Org. Chem. 2015, 11, 1259–1264, doi:10.3762/bjoc.11.140
Graphical Abstract
Figure 1: Commercially available ruthenium catalysts used in RRM metathesis.
Figure 2: Crystal structure of 5 with thermal ellipsoids drawn at 50% probability level.
Scheme 1: Synthesis of hexacyclic compound 6a by using an RRM approach.
Scheme 2: Synthesis of hexacyclic compound 11 by using an RRM route.
Beilstein J. Org. Chem. 2015, 11, 1123–1128, doi:10.3762/bjoc.11.126
Graphical Abstract
Figure 1: Natural and non-natural products containing quinane systems.
Figure 2: Quinane building blocks (1–3) and metathetic catalyst used in our strategy.
Scheme 1: Synthesis of tricyclic diones 5 and 2.
Figure 3: Retrosynthetic approach to aza-polyquinane 6 and spiro-polyquinane 7.
Scheme 2: Synthesis of the diindole derivative 9 Reagents and conditions: (i) TA:DMU, PhNHNH3Cl, 70 °C, 6 h, ...
Scheme 3: Synthesis of the macrocyclic aza-polyquinane derivative 6. Reagents and conditions: (i) NaH, allyl ...
Scheme 4: Synthesis of the spiro-polyquinane 7. Reagents and conditions: (i) NaH, allyl bromide, THF, rt, 24 ...
Scheme 5: General strategy to bis-spirocycles via RCM.
Beilstein J. Org. Chem. 2014, 10, 2664–2670, doi:10.3762/bjoc.10.280
Graphical Abstract
Figure 1: Selected theoretically interesting molecules.
Figure 2: Retrosynthetic approach toward bis-annulated PCUD.
Scheme 1: The synthesis of diallylated tricyclic diene 19.
Scheme 2: The synthesis of diallylated pentacyclic dione 20.
Scheme 3: The synthesis of heptacyclic diol 22.
Figure 3: (a) Optimized structure of 22 (b) Ancient flying machine “Pushpak Viman”.
Scheme 4: The synthesis of diallylated hexacyclic diols.
Scheme 5: The attempted synthesis of heptacyclic diol via ring-rearrangement metathesis.
Beilstein J. Org. Chem. 2014, 10, 692–700, doi:10.3762/bjoc.10.62
Graphical Abstract
Scheme 1: Preparation of maleimide dipolarophiles 4a–c.
Scheme 2: Preparation of 1,3-dipole precursors 9a–d.
Figure 1: Bi-/tridentate ligands used for the optimization of the reaction conditions.
Figure 2: ORTEP diagram showing the molecular structure of 10a at 30% probability level.
Scheme 3: Plausible mechanistic pathway for the synthesis of pyrrolo[3′,4′:3,4]pyrrolo[1,2-a]furoquinolines.
Scheme 4: Synthesis of pyrrolo[3′,4′:3,4]pyrrolo[1,2-a]furoquinoline analogues under the optimized protocol.
Scheme 5: Construction of pyrrolo[3′,4′:3,4]pyrrolo[1,2-a]phenanthrolines 14a–c and of pyrrolo[1,2-a]phenanth...
Figure 3: ORTEP diagram showing the molecular structure of 14e at 30% probability level.
Beilstein J. Org. Chem. 2008, 4, No. 41, doi:10.3762/bjoc.4.41
Graphical Abstract
Scheme 1: Synthesis of 2,3,6,7-tetrabromoanthracene (4).
Figure 1: UV-spectra of 4 and commercially available anthracene in cyclohexane (9 × 10−5 mol/L).